About Tarsus Rx
Tarsus Rx is a company based in Irvine (United States) founded in 2017 was acquired by Portage Biotech in July 2022. Tarsus Rx has raised $60 million across 1 funding round from investors including Frazier Healthcare Partners, Portage Biotech and Vivo Capital. The company has 323 employees as of December 31, 2024. Tarsus Rx offers products and services including XDEMVY, TP-04, and TP-05. Tarsus Rx operates in a competitive market with competitors including Aperta Biosciences, among others.
- Headquarter Irvine, United States
- Employees 323 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Tarsus Pharmaceuticals, Inc.
-
Annual Revenue
$182.95 M (USD)948.62as on Dec 31, 2024
-
Net Profit
-$115.55 M (USD)14.97as on Dec 31, 2024
-
EBITDA
-$119.34 M (USD)16.12as on Dec 31, 2024
-
Total Equity Funding
$60 M (USD)
in 1 rounds
-
Latest Funding Round
$60 M (USD), Series B
Jan 08, 2020
-
Investors
Frazier Healthcare Partners
& 6 more
-
Employee Count
323
as on Dec 31, 2024
-
Acquired by
Portage Biotech
(Jul 07, 2022)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Tarsus Rx
Tarsus Rx is a publicly listed company on the NASDAQ with ticker symbol TARS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Tarsus Rx
Tarsus Rx offers a comprehensive portfolio of products and services, including XDEMVY, TP-04, and TP-05.
FDA-approved treatment for Demodex blepharitis eye condition
Potential treatment for ocular rosacea inflammatory condition
Investigational option for preventing Lyme disease transmission
People of Tarsus Rx
Unlock access to complete
Software Development Team
56 people
Leadership Team
33 people
Sales and Marketing
14 people
Legal and Compliance
9 people
Human Resources and Administration
7 people
Finance and Accounting
6 people
Sr. Team
3 people
Manager Team
3 people
Unlock access to complete
Funding Insights of Tarsus Rx
Tarsus Rx has successfully raised a total of $60M through 1 strategic funding round. The most recent funding activity was a Series B round of $60 million completed in January 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Tarsus Rx
Tarsus Rx has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Frazier Healthcare Partners, Portage Biotech and Vivo Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital and private equity firm
|
Locked | Locked | Locked | |
|
Healthcare sector private equity investments are managed by the firm.
|
Locked | Locked | Locked | |
|
Flying L Partners is focused on ophthalmic sector investments.
|
Locked | Locked | Locked |
Investor details for Tarsus Rx
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Tarsus Rx
Investment portfolio details for Tarsus Rx
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Tarsus Rx
Detailed financials for Tarsus Rx
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Tarsus Rx Comparisons
Peer comparison for Tarsus Rx
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Tarsus Rx
Tarsus Rx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Aperta Biosciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Develops innovative treatments for blepharitis and ocular surface diseases through biopharma research.
|
Detailed competitors of Tarsus Rx
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Tarsus Rx
Complete news archive for Tarsus Rx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Tarsus Rx
Tarsus Rx was founded in 2017 and raised its 1st funding round 3 years after it was founded.
Tarsus Rx is headquartered in Irvine, United States. It is registered at Irvine, California, United States.
Bobak Azamian is the current CEO of Tarsus Rx.
Tarsus Rx is a funded company, having raised a total of $60M across 1 funding round to date.
As of Dec 31, 2024, the latest employee count at Tarsus Rx is 323.
Annual revenue of Tarsus Rx is $182.95M as on Dec 31, 2024.
Tarsus was founded in 2017 and is headquartered in Irvine, United States. Focus is placed on the pharmaceutical sector, specifically ophthalmology, where proprietary drugs for eye conditions are developed. The lead candidate, TP-03, a topical ophthalmic treatment for Demodex blepharitis, is advancing through Phase 2b3 clinical trials. Additional pipeline efforts target other ocular disorders, with operations centered on drug innovation and testing.
Tarsus Rx's top competitors include Aperta Biosciences.
Tarsus Rx offers XDEMVY, TP-04, and TP-05.
Yes, Tarsus Rx is publicly traded on NASDAQ under the ticker symbol TARS.
Tarsus Rx has 7 investors. Key investors include Frazier Healthcare Partners, Portage Biotech, Vivo Capital, Flying L Partners, and Visionary Ventures.
The ticker symbol of Tarsus Rx is TARS on NASDAQ.